Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study | Zendy

T. Willigenburg | Zendy; Ellis Beld | Zendy; Jochem Hes | Zendy; J J W Lagendijk | Zendy; Hans C.J. de Boer | Zendy; Marinus A. Moerland | Zendy; Jochem R.N. van der Voort van Zyp | Zendy

Open Access

Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study

Author(s) -

T. Willigenburg,

Ellis Beld,

Jochem Hes,

J J W Lagendijk,

Hans C.J. de Boer,

Marinus A. Moerland,

Jochem R.N. van der Voort van Zyp

Publication year - 2020

Publication title -

physics and imaging in radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.777

H-Index - 12

ISSN - 2405-6316

DOI - 10.1016/j.phro.2020.07.006

Subject(s) - medicine , nuclear medicine , brachytherapy , rectum , radiation treatment planning , magnetic resonance imaging , prostate cancer , radiation therapy , prostate , radiology , cancer , surgery

Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) is one of the treatment options for radiorecurrent localized prostate cancer. However, due to the invasive nature of the treatment, not all patients are eligible. Magnetic resonance linear accelerator (MR-Linac) systems open up new treatment possibilities and could potentially replace FS-HDR-BT treatment. We conducted a planning study to investigate the feasibility of delivering a single 19 Gy dose to the recurrent lesion using a 1.5 Tesla MR-Linac system.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research